CTOs on the Move

LifeMine Therapeutics

www.lifeminetx.com

 
For thousands of years, people have discovered medicines from fungi by brewery. This approach has led to transformative medicines that saved millions of lives and have altered the course of medical history. Drug discovery by brewery proved to be difficult and time-consuming, leaving the field in search of a disruptive technological solution. Our genomically-enabled drug discovery engine is precisely that solution, dramatically accelerating the search for nature’s breakthrough drugs. At LifeMine, genomicists, bioinformaticians and microbiologists identify new evolutionary solutions for disease intervention; natural products chemists access the natural molecules that inspire our drug discovery efforts; biologist and chemist drug hunters craft these ...
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.lifeminetx.com
  • 100 Acorn Park Drive 6th Floor
    Cambridge, MA USA 02140
  • Phone: 617.945.9510

Executives

Name Title Contact Details

Funding

LifeMine Therapeutics raised $55M on 09/18/2017
LifeMine Therapeutics raised $50M on 01/07/2021

Similar Companies

Corium International

Corium International is a Grand Rapids, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Protea Biosciences

Protea Biosciences is a Morgantown, WV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

pangenex

pangenex is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Talaris Therapeutics

Talaris Therapeutics is a late-clinical stage biotechnology company based in Boston, MA and Louisville, KY. Talaris is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe auto-immune and immune-mediated disorders. The company was founded on technology discovered and developed by Dr. Suzanne Ildstad and operates its own cell processing facility in Louisville. Talaris is backed by leading life sciences investors Blackstone Life Sciences, Longitude Capital and Qiming Venture Partners USA.

Regen BioPharma

The focus of Regen BioPharma, Inc. is to developing translational medicine platforms for the rapid commercialization of stem cell therapies and to advance intellectual property licensed from entities, institutions and universities that show promise towards fulfilling the purpose of increased quality of life. Regen BioPharma has reviewed more than 20,000 US issued patents covering stem cell related subject matter, created a shortlist of 30 promising technologies for rapid commercialization, and currently is in negotiations to license several of these. The Regen BioPharma business model is to take multiple stem cell therapeutics to and through the human "safety and signal of efficacy" stage (Phase I/II clinical trials), followed by exit. Having assembled a core infrastructure specialized in obtaining regulatory approval and executing clinical trials in cell therapy, we aim to act as a "superincubator" that within 1-2 years grows technologies from laboratory to an asset ready for spin-off or sale.